External validation of the predictive performance of population pharmacokinetic models for phenobarbital in pediatric patients

Aim Several studies have reported population pharmacokinetic models for phenobarbital (PB), but the predictive performance of these models has not been well documented. This study aims to do external validation of the predictive performance in published pharmacokinetic models.

Methods Therapeutic drug monitoring data collected in neonates and young infants treated with PB for seizure control, was used for external validation. A literature review was conducted through PubMed to identify population pharmacokinetic models. Prediction- and simulation-based diagnostics, and Bayesian forecasting were performed for external validation. The incorporation of size or maturity functions into the published models was also tested for prediction improvement.

Results A total of 79 serum concentrations from 28 subjects were included in the external validation dataset. Seven population pharmacokinetic studies of PB were selected for evaluation. The model by Voller et al. [27] showed the best performance concerning prediction-based evaluation. In simulation-based analyses, the normalized prediction distribution error of two models (those of Shellhaas et al. [24] and Marsot et al. [25]) obeyed a normal distribution. Bayesian forecasting with more than one observation improved predictive capability. Incorporation of both allometric size scaling and maturation function generally enhanced the predictive performance, but with marked improvement for the adult pharmacokinetic model.

Conclusion The predictive performance of published pharmacokinetic models of PB was diverse, and validation may be necessary to extrapolate to different clinical settings. Our findings suggest that Bayesian forecasting improves the predictive capability of individual concentrations for pediatrics.

What is already known about this subject

• Pharmacokinetics of phenobarbital (PB) have been reported large inter-individual difference and treatment with PB required therapeutic drug monitoring.

• Population pharmacokinetic models for PB have been studied by several researchers but predictive performance of these models has not been well documented.

What this study adds

• Predictive performance of pharmacokinetic models of phenobarbital (PB) was various and required validation for extrapolation to different clinical settings.

• Bayesian forecasting could improve the predictability for individual drug concentrations.

• Imputation of both size and maturation functions could help to enhance the predictability of pharmacokinetic models for pediatric patients.